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Abstract: Asthma is a chronic inflammatory disease characterized by profound extracellular matrix changes 
referred to as bronchial remodelling. In this study, we evaluated matrix metalloproteinases (MMPs) and tissue 
inhibitors of MMPs (TIMPs) mRNA expression in bronchial secretions of asthmatics and correlated MMPs 
modulations with the lung function as a reflection of the bronchial extracellular matrix remodelling. Quantitative 
RT-PCR was performed on cell pellets obtained from induced sputum in order to detect the mRNAs for MMP-1, 
-2, -3, -8, -9, -12, -13 TIMP-1, -2, while semiquantitative RT-PCR was performed to assess the expression of 
MMP-7, monocyte chemoattractant protein-1 (MCP-1) and transforming growth factor-β1 (TGF-β1). The mRNA 
transcripts for MMP-1, TIMP-1 and monocyte chemoattractant protein-1 (MCP-1) were increased in cell pellets 
of induced sputum from asthmatics when compared to controls (P 0.05), and the intensity of MMP-1 mRNA 
expression inversely correlated with the FEV1 in asthmatics (r = -0.49, P<0.05). The MMP-1 mRNA/TIMP-1 
mRNA ratio correlated with the levels of MCP-1 mRNA in asthmatics (r = 0.47, P<0.05). There were no 
differences between the groups with respect to mRNA coding for MMP-2, -3, -7, -8, -9, -12, -13, -14, TIMP-2 
and TGF-β1. We conclude that cells contained in the bronchial secretions from asthmatics express higher 
amounts of mRNA for MMP-1 and TIMP-1, perhaps related to an increased expression of MCP-1, which might 
contribute to the extracellular matrix changes observed during airway remodelling.  
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Matrix metalloproteases (MMPs) compose an at least 26 member family of zinc-containing enzymes produced 
by many cell types and sharing structural and functional features. They are secreted from cells as inactive 
zymogens, bear a Zn atom at the active site, are made of five domains and are inhibited by the tissue inhibitors of 
MMPs (TIMPs).1 The MMPs are able to degrade the extracellular matrix components with a variable affinity 
depending on the subclasses. Recently, it has been shown that MMPs may participate in the fine tuning and 
repair process through regulation of the activity of chemokines/ cytokines and growth factors such as IL-8, IL-1β 
and insulin-like growth factor-1 (IGF-1).2,3 TIMPs are a family of four members that inhibit the MMPs in a 1:1 
relation.4
Asthma is an inflammatory disease of the airways, leading to progressive lung function impairment.5 In the last 
decade, interest has risen about the morphological changes that occur in the bronchial tree of such patients 
implicating profound extracellular matrix modifications and referred to as bronchial remodelling.6,7
Recently, it has been demonstrated that MMPs are likely to contribute to the pathogenesis of asthma. Indeed, 
many MMPs, including MMP-1, -2, -3, -8 and -9, have been detected by various methods in the airways or the 
lung of such patients.8-10 In a mouse model of asthma, Kumagai et al11 have demonstrated that treating mice with 
broad-spectrum synthetic MMP inhibitors decreased the allergen-induced inflammation. In a similar model, we 
have demonstrated that MMP-9 KO mice did not develop airway hyperresponsiveness and displayed less 
peribronchial inflammation.12 Using a murine asthma model, Oh et al13 have recently reported that the 
plasminogen activator inhibitor-1 (PAI-1)-dependent inhibition of MMP-9 is a mechanism preventing the 
extracellular matrix deposition in the bronchial walls. It has been reported that MMP-9 and its inhibitor TIMP-1 
were increased at the protein level in the lungs from asthmatics,8-10,14-16 and that bronchoalveolar lavage (BAL)-
issued macrophages from asthmatics produce more MMP-917 and TIMP-118 than controls. In addition, when 
compared to controls, asthmatics had in their bronchial secretions a lower MMP-9/TIMP-1 ratio measured by 
ELISA, which was found to be proportional to the disease severity.16 Nevertheless, other authors using 
immunohistochemistry described that MMP-9 was predominant over TIMP-1 in the bronchial walls of 
asthmatics.14 Regulation of MMPs expression and production is the result of a complex network of reciprocal 
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interactions between different mediators and cells. Among these pathways, monocyte chemoattractant protein-1 
(MCP-1) and transforming growth factor-β1 (TCF-β1), two mediators reported to be increased in the bronchial 
tree from asthmatics,19,20 have been demonstrated to induce the expression of MMP-1 in different cell types.21,22
We hypothesized that the upregulation of some MMPs and TIMPs genes expression in the sputum cells 
correlates with an increased bronchial remodelling and, therefore, with the lung function tests. The purpose of 
the present study was then to investigate the MMPs and TIMPs production at the mRNA level in the bronchial 
secretions, and to correlate this production with the sputum cellular content and the baseline lung function in 
asthmatics. 
Materials and methods 
Subjects 
In all, 22 asthmatics and nine healthy controls participated in this study (Table 1). The patients were classified as 
suffering from mild asthma according to the American Thoracic Society (ATS) criteria (ATS guidelines for the 
diagnosis of asthma23). None of the controls and asthmatics were current or previous smokers (Table 1). None of 
the subjects enroled in this study had suffered from a bronchial infection or from an asthma exacerbation for the 
6 weeks preceding the study. All subjects gave their written informed consent and the protocol of the study was 
approved by the local ethical committee. 
Sputum Induction and Processing 
Sputum induction was performed as described previously8 by inhalation of hypertonic saline (NaCl 4.5%) after 
premedication by 400 µg inhaled salbutamol. Aerosols were generated by an ultrasonic nebulizer (Devilbiss neb 
2000) for 20 min, the output of which was set at 1.5ml/min. Samples were collected in a sterile and RNAse-free 
Petri dish, immediately placed at 4°C and processed in maximum 15 min. The samples were diluted twice with 
dithiothreitol 5 mM (DTT, Calbiochem) diluted in phosphate-buffered saline (PBS). The samples were then 
centrifuged at 400g for 10 min at 4°C in order to separate the cellular and the fluid phase. Cell pellets were 
mixed with a solution of guanidine thiocyanate (5 M), snap frozen in liquid nitrogen and stored at -80°C until the 
mRNA extraction (see below). Cell counts were performed on cytospins stained with Diff Quicko (Dade) using 
morphological criteria and the supernatants were stored at -80°C. In all cases, 400 nonsquamous nucleated cells 
were counted by an experimented observer blinded to clinical details. 
Table 1: Patient characteristics 
 Controls Asthma 
N 9 22 
Mean age 31 (23-40) 35 (18-65) 
Sex ratio (M/F) 4/5 14/8 
Tobacco 9 NS 22 NS 
FEV1 (% pred) 92 (82-114) 89 (36-123) 
FEV1 (ml) 3670 (2430-4130) 3366 (1164-4920) 
FEV1/VC 81 (72-97) 76 (39-94) 
KCO (%) ND 88 (55-116) 
PC20M   
(Geometric mean) >16 0.79 
Therapy 9NT 22 NT 
Values are expressed as mean (range). 
NT = not treated (salbutamol as needed); NS = nonsmoker, ND = not done; KCO = transfer coefficient for CO; PC20 M = provocative dose of 
methacholine causing a 20% fall in FEV1
 
RT-PCR for MMPs, TIMPs, MCP-1 and TGF-β1 Transcripts 
Total RNA was obtained from the sputum cell pellets by using the cesium chloride ultracentrifugation method24 
allowing the removal of mucous DNA. RNA levels and purity were assessed using a smartspect 3000 
spectrophotometer (BioRad, Hercules, CA, USA). In order to rule out the possibility of genomic DNA 
contamination, all our RNA samples underwent a PCR with primers amplifying the 28S DNA. 28S ribosomal 
RNA (rRNA) and MMPs, TIMPs, MCP-1 and TCF-β1 mRNAs were measured in 10 ng aliquots of total RNA by 
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RT-PCR. A known copy number of external control RNA template (synthetic RNA) was introduced in each 
sample to monitor the RT-PCR reaction and to allow the quantitation of each endogenous mRNA.25 RT-PCR 
was performed using the GeneAmp Thermostable rTth reverse transcriptase RNA PCR kit (Perkin-Elmer, 
Branchburg, NJ, USA) and two pairs of primers (Gibco BRL-Life Technologies) (Table 2). Reverse transcription 
was performed at 70°C for 15 min followed by 2 min incubation at 95°C for denaturation of RNA-DNA 
heteroduplexes. Amplification started at 94°C for 15 s, 68°C for 20 s and 72°C for 10 s and terminated by 2 min 
at 72°C. RT-PCR products were resolved on 10% acrylamide gels and analysed using a Fluor-S MultImager 
(Bio-Rad, Hercules, CA, USA) after staining with Gelstar dye (FMC Bioproducts, Rockland, ME, USA). 
Quantitative RT-PCR results are expressed as a ratio between the intensities of the bands corresponding to the 
endogenous RNA and to a synthetic RNA added in the RT-PCR reaction in known amounts.25 This ratio 
calculated for an MMP is further divided by the same ratio calculated for 28S rRNA in the same sample. The 
results showed are mean of duplicates. MCP-1 and TGF-β1 RT-PCR were quantified by reporting the intensity of 
the band measured on a polyacrylamide gel to that of a 28S rRNA in the corresponding sample (semiquantitative 
assessment). 
 
Table 2: Characteristics of RT-PCR reaction 











MMP-1 5'-GAGCAAACACATCTGAGGTACAGGA-3' 5'-TTGTCCCGATGATCTCCCCTGACA-3' 36 267 185 
MMP-2 5'-AGATCTTCTTCTTCAAGGACCGGTT-3' 5'-GGCTGGTCAGTGGCTTGGGGTA-3' 36 271 225 
MMP-3 5'-GATCTCTTCATTTTGGCCATCTCTTC-3' 5'-CTCCAGTATTTGTCCTCTACAAAGAA-3' 35 272 246 
MMP-7 5'-CCCCCCTGCATTTCAGGAA-3' 5'-TCCTGGCCCATCAAATGG-3' 30 — 100 
MMP-8 5'-CCAAGTGGGAACGCACTAACTTGA-3' 5'-TGGAGAATTGTCACCGTGATCTCTT-3 ' 36 267 200 
MMP-9 5'-GCGGAGATTGGGAACCAGCTGTA-3' 5'-GACGCGCCTGTGTACACCCACA-3' 35 266 208 
MMP-12 5'-ACATTTCGCCTCTCTGCTGATGAC-3' 5'-CAGAAACCTTCAGCCAGAAGAACC-3' 36 262 201 
MMP-13 5'-ATGATCTTTAAAGACAGATTCTTCTGC-3' 5'- TGGATAACCTTCCAGAATGTCATAA-3' 38 270 203 
MMP-14 5'- GGATACCCAATGCCCATTGGCCA-3' 5'-CCATTGGGCATCCAGAAGAGAGC-3' 32 269 221 
TIMP-1 5'-CATCCTGTTGTTGCTGTGGCTGAT-3' 5'-GTCATCTTGATCTCATAACGCTGG-3' 35 295 176 
TIMP-2 5'-CTCGCTGGACGTTGGAGGAAAGAA-3' 5'-AGCCCATCTGGTACCTGTGGTTCA-3' 29 269 155 
MCP-1 5'-TAGCAGCCACCTTCATTCCCCAAG-3' 5'-GTCTGGGGAAGGCTAGGGGAAAAT-3' 38 — 182 
TGF-β1 5'-ACTACTACGCCAAGGAGGTCAC-3' 5'-ACGTGCTGCTCCACTTTTAACT-3 ' 38 — 202 
28S 5'-GTTCACCCACTAATAGGGAACGTGA-3' 5'-GATTCTGACTTAGAGGCGTTCAGT-3' 19 269 212 
 
Statistical Analysis 
Comparisons between the groups were performed by a Mann-Whitney test. The correlations were sought by 
calculating the Spearman's coefficient of correlation. P-values <5% were considered as statistically significant. 
Results 
Demographic Characteristics of Patients 
The mean ages of patients with asthma and controls were similar. The asthmatics were classified as having mild 
asthma according to the guidelines of the ATS (ATS guidelines for the diagnosis of asthma,23). Most of the 
asthmatics had a normal basal lung function and the mean FEV1 was not significantly different from that of 
controls. None of the asthmatics had been treated by inhaled or oral steroids within the last 6 weeks or reported a 
smoking history (Table 1). 
Total and Differential Cell Counts in Induced Sputum 
Sputum cell counts are shown as both absolute cell counts (cell number/g of sputum) and percentages of total 
cell counts (Table 3). As expected, eosinophil counts were higher in asthmatics when considering both the 
percentage or absolute cell counts (P<0.005). 
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Table 3:  Total and differential sputum cell counts 
 Controls Asthma 
Sputum weight (gr) 2.67 (0.75-6.7) 4.35 (1.43-8.92) 
Viability (%) 92 (71-100) 92 (77-100) 
Squamous cells (%) 5 (1-13) 10 (0-33) 
Total nonsquamous 
cells (103/g) 
1310 (150-2180) 1150 (260-25 390)
Macrophages (%) 59.8 (25-71) 41.6 (4-83) 
Macrophages (103/g) 764 (334-1245) 550 (85-5388) 
Eosinophils (%) 0.1 (0-7.2) 5.2** (0-67) 
Eosinophils (103/g) 2 (0-94) 59** (0-3555) 
Neutrophils (%) 19.5 (7.2-55) 23.2 (1.4-80.6) 
Neutrophils (103/g) 213 (81-1150) 343 (7-20 464) 
Lymphocytes (%) 4.4 (2.4-13) 1.8** (0-5.2) 
Lymphocytes (103/g) 62 (28-170) 16* (0-196) 
Epithelial cells (%) 6.8 (1.8-33.2) 8 (1.4-48.4) 
Epithelial cells (103/g) 109 (32-375) 145 (25-465) 
The results are expressed as median (range) for both percentages and absolute values *P<0.05 vs controls. **P<0.005 vs controls. 
 
Figure 1:  mRNA levels in the extracts from cell pellets measured in quantitative RT-PCR. The results are 
expressed in arbitrary units, corresponding to a ratio between the number of mRNA copies and 28S rRNA for 
each sample. The horizontal bars represent the median values. 
 
Published in: Laboratory Investigation: Journal of Technical Methods & Pathology (2004), vol.84, iss.4, pp. 418-424 
Status: Postprint (Author’s version) 
MMPs, TIMPs, MCP-1 and TGF-β1 mRNA Expression by Sputum Cells 
The mRNA transcripts for MMP-1, TIMP-1 and MCP-1 were significantly increased in the sputum cell pellets 
from asthmatics (P<0.05) (Figures 1a-c and 2). MCP-1 mRNA levels were significantly correlated with MMP-1 
mRNA/TIMP-1 mRNA ratio in asthmatics (r = 0.47, P<0.05) (Figure 3). MMP-9 and -12 mRNA levels were not 
significantly modified in asthmatics when compared to controls (Figure 1 d,e). MMP-2, -7, -14, TIMP-2 and 
TGF-β1 mRNA levels were detectable in each sample without any significant difference between the groups 
(data not shown). MMP-8 mRNAs were barely detectable and have not been quantified, while those for MMP-3 
and -13 were not detectable in our samples. The calculated ratio between the number of mRNA copies of MMP-
9 and TIMP-1 was not different between the groups. 
Correlations between Sputum MMPs, TIMPs and FEV1
In asthmatics, MMP-1 mRNA levels were negatively correlated with baseline FEV1 (r = -0.49, P<0.05) (Figure 
4). 
 
Figure 2: Representative examples of RT-PCR for MMP-1 mRNA performed on 10 ng aliquots of RNA extracted 
from sputum cells from five control subjects and five asthmatics. The upper band (267 bp) corresponds to the 
internal standard, made of a synthetic RNA (see Materials and methods) and added in known amounts in the RT-
PCR reaction, while the lower band (185 bp) represents the endogenous RNA amplification. 10% 
polyacrylamide gels are stained with Gelstar®.  
 
 
Figure 3: Relationship between the MMP-lmRNA/TIMP-1 mRNA ratio and the expression levels of MCP-1 
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Figure 4: Relationship between the levels of MMP-1 mRNA expression and baseline FEV1 expressed as % 
predicted in sputum cells from asthmatics. 
 
Discussion 
We describe here for the first time that mRNA transcripts for MMP-1 and TIMP-1 are increased in the sputum 
cells from asthmatics. Furthermore, we demonstrate that the amounts of MMP-1 mRNA transcripts are related to 
FEV1 impairment in asthmatics. 
MMP-1 is mainly secreted by fibroblasts and activated monocytes/macrophages.26,27 MMP-1 was shown to be 
overexpressed in the lungs of patients with emphysema27 and COPD28 but not in asthmatics, although MMP-1 
protein was barely detectable in BAL fluid from latter.10 Although it displays a rather limited proteolytic 
spectrum when considering the extracellular matrix, MMP-1 is a major protease capable of degrading fibrillar 
collagen, and the increased levels of MMP-1 gene expression could be associated in asthmatics with the 
bronchial remodelling that mainly consists of cycles of degradation and impaired repair.6 In addition, MMP-1 is 
likely to play roles other than breaking down fibrillar collagen. In particular, it can also degrade insulin-like 
growth factor binding proteins (IGF-BP)-1 and -3, thereby increasing the bioavailability of IGF-1, a potent 
growth factor for airway smooth muscle.3 Our observation of increased expression of MMP-1 in asthma is in line 
with a recent report demonstrating an overexpression of MMP-1 mRNA by human monocytes when stimulated 
by Th2 polarized lymphocytes.29 Our study should be confirmed by immunohistochemistry or Western blot in 
order to assess the protein production of MMP-1. The reason why mRNA for MMP-1 was increased in asthma 
could be linked to the action of some proinflammatory cytokines encountered in asthma that are known to be 
able to upregulate the MMP-1 gene expression in different cells. For instance, it has been shown in an animal 
model of asthma that the specific inhibition of MCP-1 diminishes drastically bronchial airway 
hyperresponsiveness and inflammation.30 In the present study, we describe an increased mRNA expression for 
MCP-1 in sputum cells from asthmatics and we found a correlation between MCP-1 expression and the ratio 
between MMP-1 and TIMP-1 mRNA, indicating that MCP-1 may account for an increased MMP-1 proteolytic 
activity, and thereby participate in the inflammation and remodelling processes of the airways that take place in 
asthma. However, the relationship between the two expressions is not demonstrated by our data and one can 
speculate that MCP-1 could increase MMP-1 expression in the sputum cells simply by a chemotactic effect 
increasing the macrophage number in the airway lumen. However, in the present study there were no significant 
differences in macrophage counts between asthmatics and controls, indicating that such a chemotactic effect of 
MCP-1 is not the main cause of MMP-1 overexpression. 
In our previous studies,8,31 both quantitative zymography and ELISA have shown that the MMP-9 protein was 
increased in the bronchial secretions from asthmatics. These raised levels of MMP-9 in sputum supernatants 
from asthmatics, which contrast with the lack of increased mRNA expression from sputum cells, point to an 
excessive release of the protein from intracytoplasmic stores. Knowing that neutrophils may synthesize high 
amounts of MMP-9 and store it in the secondary granules,24,32 the absence of MMP-9 mRNAs enhancement in 
the sputum cells from asthmatics could be ascribed to a neutrophil degranulation process occurring in the 
airways from those patients perhaps enhanced by a neutrophil activation. In addition, MMP-9 released from 
neutrophils may in turn amplify the neutrophils recruitment by processing the interleukin-8 (IL-8) by cleaving 
six amino acids, resulting in an IL-87-77 being 10 times more potent chemoattractant for neutrophils.2 However, it 
is worth to note that the cellular origin of MMP-9, which appears as one of the major proteases present in the 
airways of asthmatics, is likely to be plural. Indeed, other authors have described an overproduction of MMP-9 
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by other cell types such as epithelial cells, macrophages and eosinophils in asthma.15,17,33 An alternative 
explanation for dissociated MMP-9 levels in proteins and mRNAs would be that the proportion of migrating 
epithelial cells secreting high levels of MMP-9 in the bronchial lumen and secretions is increased in asthmatics.34 
Nevertheless, it should be kept in mind that the detection of the expression of mRNAs corresponding to such 
proteins does not necessarily implicate that the protein is effectively secreted by cells. 
In line with our previous findings of increased TIMP-1 protein levels in the sputum from asthmatics,8 TIMP-1 
mRNA expression is increased in the sputum from asthmatics. Besides confirming the previous works indicating 
that TIMP-1 is increased in the bronchial secretions of asthmatics8,16,18 we are adding new data regarding TIMP-
1 mRNA expression in the airways. TIMP-1 is a potent inhibitor of MMP-1 and -9 and is secreted by many cell 
types. Recently, it has been demonstrated that MMP-9 originating from neutrophils is in part complexed to its 
inhibitor, TIMP-1,35 and that TIMP-1 is produced by neutrophils,24 and stored in specific cytoplasmic vesicles.36 
However, as discussed earlier for MMP-9, TIMP-1 might also originate from other cells and namely from 
macrophages.10
We did not find at the mRNA level the decreased MMP-9/TIMP-1 ratio previously reported at the protein level 
in asthma.16 This could be explained by the fact that our asthmatic patients were stable asthmatics and less severe 
in terms of function loss than those previously studied, and that we have studied mRNA levels that could not 
reflect the MMP-9 and TIMP-1 protein secretion from intracellular stores, for example.32,35 It is also worth 
noting that a study conducted on bronchial biopsies from asthmatics showed that MMP-9 immunoreactivity was 
higher than that of TIMP-1 in the epithelium and submucosa, which is probably another compartment, not 
explored by the study of sputum.14 We acknowledge that the MMP/TIMP ratios are not equivalent when 
considered at protein or mRNA level and could not reflect the real state of activation of the proteins. 
A rather unusual finding of this study is the fact that asthmatics display lower lymphocyte counts than healthy 
subjects in their sputum. Although unusual, this finding has previously been reported in other papers37 and many 
reports have described that the lymphocyte counts are poorly reproducible.38,39
In conclusion, our results indicate that induced sputum cells collected from asthmatics displayed an increased 
transcription for MMP-1 and TIMP-1. This excessive transcription of matrix metalloprotease may significantly 
contribute to airway remodelling in asthma and suggest applying an animal model of asthma to human MMP-1 
expressing transgenic mice40 in order to investigate the precise effects of MMP-1 overexpression on the 
bronchial wall extracellular matrix composition in the context of a repeated allergen exposure. 
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